BioSpace News Archive

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Insmed Incorporated today announced the granting of inducement awards to 10 new employees.

SK bioscience announced that Richard Kensinger, PhD, former Director and Head of Drug Substance Process Development in Sanofi Pasteur and former Executive Director of Process Development and Protein Sciences at Affinivax Inc. has joined in ‘SK bioscience USA Inc.’ as Vice President of R&D Project Management.

Umbra Applied Technologies Group, Inc. announce that its subsidiary, Ossifix Orthopedics has begun a comparative study with doctors across six different sites.

Schrödinger, Inc. today reported that on January 16, 2023, the company granted (i) non-statutory stock options to purchase an aggregate of 14,300 shares of the company’s common stock to six newly hired employees, including three newly hired employees based outside of the United States and (ii) restricted stock units (RSUs) with respect to 4,350 shares of the company’s common stock to one newly hired employee.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition’s Nu.Q® Vet commercial strategy.

Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has entered into warrant inducement offer letters (the “Inducement Offer Letters”) to raise approximately $1.0 million in gross proceeds from the exercise of warrants to purchase 4,808,595 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), in the aggregate.

Heart Test Laboratories, Inc. d/b/a HeartSciences announced that Andrew Simpson, Chief Executive Officer of HeartSciences, will be participating in the Healthcare IT Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, being held virtually on Wednesday, January 25th, 2023.

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.

Able Medical Devices today announced the launch of Valkyrie® Looped Sternotomy Sutures.